urea has been researched along with Dementia in 19 studies
pseudourea: clinical use; structure
isourea : A carboximidic acid that is the imidic acid tautomer of urea, H2NC(=NH)OH, and its hydrocarbyl derivatives.
Dementia: An acquired organic mental disorder with loss of intellectual abilities of sufficient severity to interfere with social or occupational functioning. The dysfunction is multifaceted and involves memory, behavior, personality, judgment, attention, spatial relations, language, abstract thought, and other executive functions. The intellectual decline is usually progressive, and initially spares the level of consciousness.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 9.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| "We report a successful case of sedation during spinal anesthesia using continuous administration of landiolol and dexmedetomidine in a patient with severe dementia." | 7.81 | [Successful sedation with landiolol and dexmedetomidine during spinal anesthesia in a patient with active dementia]. ( Deguchi, S; Fujiwara, S; Kido, H; Komasawa, N; Minami, T, 2015) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 6.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0." | 6.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "In a trial that was stopped early for efficacy, patients with dementia-related psychosis who had a response to pimavanserin had a lower risk of relapse with continuation of the drug than with discontinuation." | 5.41 | Trial of Pimavanserin in Dementia-Related Psychosis. ( Ballard, C; Cummings, JL; Devanand, DP; Erten-Lyons, D; Foff, EP; McEvoy, B; Soto-Martin, ME; Stankovic, S; Sultzer, DL; Tariot, PN; Weintraub, D; Youakim, JM, 2021) |
| " Mortality analyses were adjusted for age, sex, levodopa equivalent daily dose (LEDD), and dementia." | 4.31 | Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis. ( Alakkas, A; Liu, L; Longardner, K; Nahab, FB; Wright, BA; Xu, R; You, H, 2023) |
| "Active cancer, dementia, and high values for urea and RDW at admission are predictors of one-year mortality in patients hospitalized for HF." | 4.31 | One-year mortality after hospitalization for acute heart failure: Predicting factors (PRECIC study subanalysis). ( Lopes Ramos, R; Marques, I; Mendonça, D; Teixeira, L, 2023) |
| "We report a successful case of sedation during spinal anesthesia using continuous administration of landiolol and dexmedetomidine in a patient with severe dementia." | 3.81 | [Successful sedation with landiolol and dexmedetomidine during spinal anesthesia in a patient with active dementia]. ( Deguchi, S; Fujiwara, S; Kido, H; Komasawa, N; Minami, T, 2015) |
| "Pimavanserin may prove beneficial in treating the hallucinations and delusions of DRP without worsening cognitive or motor function." | 2.82 | Dementia-related psychosis and the potential role for pimavanserin. ( Cummings, JL; Devanand, DP; Stahl, SM, 2022) |
| " By measuring the brain function using computer period analysis of cerebral biopotentials, dose-efficacy relations were found (in the range of 25-75 mcg) which suggest the bioavailability of LHM at the CNS level." | 2.64 | Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram. ( Akpinar, S; Herrmann, WM; Itil, TM, 1975) |
| "In a Phase 2 study with pimavanserin in Alzheimer's disease psychosis, pimavanserin significantly (p=0." | 2.58 | Pimavanserin: Potential Treatment For Dementia-Related Psychosis. ( Ballard, C; Cummings, J; Foff, E; Norton, J; Owen, R; Stankovic, S; Tariot, P; Youakim, J, 2018) |
| "Dementia associated with Parkinson's disease (PDD) is a common problem and one that is associated with significant morbidity and mortality." | 2.46 | Parkinson's disease dementia. ( Burn, DJ; Docherty, MJ, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (31.58) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 1 (5.26) | 29.6817 |
| 2010's | 3 (15.79) | 24.3611 |
| 2020's | 8 (42.11) | 2.80 |
| Authors | Studies |
|---|---|
| Tariot, PN | 2 |
| Ballard, C | 3 |
| Devanand, DP | 3 |
| Cummings, JL | 3 |
| Sultzer, DL | 2 |
| Schneider, LS | 1 |
| Longardner, K | 1 |
| Wright, BA | 1 |
| Alakkas, A | 1 |
| You, H | 1 |
| Xu, R | 1 |
| Liu, L | 1 |
| Nahab, FB | 1 |
| Marques, I | 1 |
| Lopes Ramos, R | 1 |
| Mendonça, D | 1 |
| Teixeira, L | 1 |
| Stahl, SM | 1 |
| Soto-Martin, ME | 1 |
| Erten-Lyons, D | 1 |
| Weintraub, D | 1 |
| McEvoy, B | 1 |
| Youakim, JM | 1 |
| Stankovic, S | 2 |
| Foff, EP | 1 |
| Friedman, JI | 1 |
| Liu, KY | 1 |
| Howard, R | 1 |
| Cummings, J | 1 |
| Tariot, P | 1 |
| Owen, R | 1 |
| Foff, E | 1 |
| Youakim, J | 1 |
| Norton, J | 1 |
| Deguchi, S | 1 |
| Komasawa, N | 1 |
| Fujiwara, S | 1 |
| Kido, H | 1 |
| Minami, T | 1 |
| Docherty, MJ | 1 |
| Burn, DJ | 1 |
| Belorgey, D | 1 |
| Sharp, LK | 1 |
| Crowther, DC | 1 |
| Onda, M | 1 |
| Johansson, J | 1 |
| Lomas, DA | 1 |
| Selkoe, DJ | 1 |
| Ihara, Y | 1 |
| Salazar, FJ | 1 |
| Anderton, B | 1 |
| Tokutake, S | 1 |
| Oyanagi, S | 1 |
| Itil, TM | 1 |
| Herrmann, WM | 1 |
| Akpinar, S | 1 |
| Murray, RM | 1 |
| Greene, JG | 1 |
| Adams, JH | 1 |
| Hsia, YE | 1 |
| Thomas, JH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Double-blind, Placebo-controlled, Relapse Prevention Study of Pimavanserin for the Treatment of Hallucinations and Delusions Associated With Dementia-related Psychosis[NCT03325556] | Phase 3 | 392 participants (Actual) | Interventional | 2017-09-27 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The endpoint of time from randomization to discontinuation from the DB period for any reason (other than termination of the study by the sponsor) was compared between treatment groups using a Cox regression model. The treatment effect was measured by the HR. (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
"The time from randomization to relapse in the DB period was compared between treatment groups using a Cox regression model. The treatment effect was measured by the hazard ratio (HR).~Relapse was defined as (1) ≥30% increase in SAPS-H+D total score from DB baseline (BL) and CGI-I score ≥6 relative to DB BL, (2) treatment with antipsychotic for dementia-related delusions/hallucinations, (3) treatment/study discontinuation due to lack of efficacy, and/or (4) hospitalization for worsening dementia-related psychosis.~SAPS-H+D is a 20-item scale; the total score is the sum of the 20 item scores (range 0-100); higher scores denote more severe symptoms. CGI-I is a clinician-rated 7-point scale to rate improvement in hallucinations/delusions relative to BL (range 1-7); higher scores denote less improvement or worsening.~A pre-specified IA was conducted after accrual of 40 adjudicated relapse events. The prespecified stopping criterion was met; the study was stopped for efficacy." (NCT03325556)
Timeframe: From randomization in the DB period through 26 weeks
| Intervention | days (Median) |
|---|---|
| Pimavanserin Double-Blind Period | NA |
| Placebo Double-Blind Period | NA |
4 reviews available for urea and Dementia
| Article | Year |
|---|---|
Dementia-related psychosis and the potential role for pimavanserin.
Topics: Dementia; Hallucinations; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Pimavanserin: Potential Treatment For Dementia-Related Psychosis.
Topics: Alzheimer Disease; Clinical Trials as Topic; Dementia; Humans; Mental Status and Dementia Tests; Par | 2018 |
Parkinson's disease dementia.
Topics: Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Diagnosis, Differential; Humans; Park | 2010 |
Inherited hyperammonemic syndromes.
Topics: Acidosis; Amino Acids; Ammonia; Animals; Arginine; Brain; Brain Diseases; Chemical and Drug Induced | 1974 |
2 trials available for urea and Dementia
| Article | Year |
|---|---|
Trial of Pimavanserin in Dementia-Related Psychosis.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Dementia; Double-Blind Method; Female; Hallucinations | 2021 |
Prediction of psychotropic properties of lisuride hydrogen maleate by quantitative pharmaco-electroencephalogram.
Topics: Adolescent; Adult; Aged; Biological Availability; Child; Child, Preschool; Clinical Trials as Topic; | 1975 |
13 other studies available for urea and Dementia
| Article | Year |
|---|---|
Pimavanserin and dementia-related psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2022 |
The Safety of Pimavanserin for Parkinson's Disease and Efforts to Reduce Antipsychotics for People With Dementia.
Topics: Antipsychotic Agents; Dementia; Humans; Parkinson Disease; Piperidines; Psychotic Disorders; Urea | 2022 |
Assessing the risks of treatment in Parkinson disease psychosis: An in-depth analysis.
Topics: Aged; Antipsychotic Agents; Dementia; Humans; Levodopa; Parkinson Disease; Prospective Studies; Psyc | 2023 |
One-year mortality after hospitalization for acute heart failure: Predicting factors (PRECIC study subanalysis).
Topics: Aged; Aged, 80 and over; Dementia; Erythrocyte Indices; Heart Failure; Hospitalization; Humans; Prog | 2023 |
Pimavanserin in Dementia-Related Psychosis.
Topics: Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
Pimavanserin and dementia-related psychosis: can HARMONY prevail?
Topics: Clinical Trials as Topic; Dementia; Humans; Piperidines; Psychotic Disorders; Urea | 2021 |
[Successful sedation with landiolol and dexmedetomidine during spinal anesthesia in a patient with active dementia].
Topics: Aged, 80 and over; Anesthesia, Spinal; Dementia; Dexmedetomidine; Femoral Fractures; Humans; Hypnoti | 2015 |
Neuroserpin Portland (Ser52Arg) is trapped as an inactive intermediate that rapidly forms polymers: implications for the epilepsy seen in the dementia FENIB.
Topics: Amino Acid Substitution; Arginine; Biopolymers; Catalysis; Circular Dichroism; Dementia; Epilepsy; H | 2004 |
Alzheimer's disease: insolubility of partially purified paired helical filaments in sodium dodecyl sulfate and urea.
Topics: Alzheimer Disease; Cerebral Cortex; Cytoskeleton; Dementia; gamma-Glutamyltransferase; Humans; Micro | 1982 |
Untangling insoluble filaments.
Topics: Acyltransferases; Alzheimer Disease; Dementia; Guanidine; Guanidines; Humans; Neurofibrils; Octoxyno | 1983 |
Mechanical instability of Pick bodies and their isolation in an intact form using urea solution.
Topics: Brain; Dementia; Female; Hematoxylin; Humans; Inclusion Bodies; Microscopy, Electron; Middle Aged; N | 1993 |
Analgesics abuse and dementia.
Topics: Aged; Analgesics; Aspirin; Brain; Dementia; Female; Humans; Intelligence Tests; Male; Middle Aged; P | 1971 |
Values of serum iron in patients over sixty.
Topics: Aged; Anemia, Hypochromic; Anemia, Pernicious; Arthritis, Rheumatoid; Circadian Rhythm; Dementia; Fe | 1971 |